Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Rapamycin.
- Who it may be relevant to
- Registry conditions: Familial Adenomatous Polyposis. Basic parameters: 12 years — 17 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis.
Overview
The hypothesize of this research is that rapamycin is effective and well-tolerated in teenagers with familial adenomatous polyposis (FAP). Rapamycin could be effective in blocking the formation of adenomas and/or their evolution by decreasing their size and number. Researchers aim to assess the safety profile of rapamycin in FAP adolescents using a 2 low dose regimen.
Detailed description
FAP is a rare genetic disease linked to mutations of APC gene. Adenomatous polyps appear around the age of 10 and will evolve into colic adenocarcinoma. To date, there is no effective treatment; 100% of patients will develop colorectal cancer before 40 years. This risk is addressed by regular colonoscopy monitoring, in order to propose a timely prophylactic colectomy.
Rapamycin (sirolimus) is a drug that targets the mTOR (mammalian target of rapamycin) protein involved in the PI3K-Akt signalling pathway downstream of PI3K. There are interactions between the PI3K-Akt pathway and the Wnt/APC/-catenin pathway that is hyperactivated in FAP. Rapamycin was used out of indication with efficacy and good tolerance in 2 adolescents whose parents had refused colectomy. Researchers recently demonstrated its effectiveness in a child with very severe juvenile polyposis. Data are also available in animals, but no proof-of-concept studies have been conducted in humans.
In France, Rapamycin use is allowed in adults with kidney transplantation and pulmonary lymphangioleiomyomatosis. However, it is used on children over the market. According to the literature and the field experience, the hypothesize is that a through level of 3-8 ng/ml should be effective in children with FAP, with a lower rate of adverse events.
Interventions
- Drug Rapamycin
This is a 2-dose rapamycin safety study, with a target through level of 3 to \<5 ng/ml for the first 3 months and 5-8 ng/ml for the next 3 months for each of the included patients. To avoid the possible cumulative effect, the two treatment phases will be separated by a 3-weeks wash-out period.
Primary outcome measures
- Evaluation of the safety profile of two doses of rapamycin in adolescents with Familial Adenomatous Polyposis. [Time frame: For the entire duration of taking the experimental drug (rapamycin) and up to one month after stopping.]
Secondary outcome measures (3)
- Evaluation of the effect of rapamycin on the number of polyps, on the entire colon and by segments (rectum, left colon, transverse colon and right colon) in adolescents suffering from Familial Adenomatous Polyposis [Time frame: Visit 1 inclusion and 6 month after]
- Evaluation of the effect of rapamycin on the size of polyps, on the entire colon and by segments (rectum, left colon, transverse colon and right colon) in adolescents suffering from Familial Adenomatous Polyposis. [Time frame: Visit 1 inclusion and 6 month after]
- Evaluation of the effect of rapamycin on the size of the largest polyp in each segment (rectum, left colon, transverse colon and right colon) in adolescents with Familial Adenomatous Polyposis [Time frame: After 6 months of treatment with rapamycin]
Eligibility criteria
Inclusion criteria
- Children aged 12 to 17 at time of inclusion.
- Patients with colonoscopy for diagnosis or follow-up of FAP.
- ≥ 5 polyps (> 2 mm) at initial colonoscopy (V1).
- Free and informed consent, signed by both holders of parental authority/legal representative, with the accord of the minor patient.
- Affiliated with a social security scheme.
- Patients of childbearing potential must agree to the use of a method of contraception during the study.
Exclusion criteria
- Inability to understand the nature and goals of the study and/or communication difficulties observed by the investigator.
- Contraindication to performing a colonoscopy.
- < 5 polyps (>2 mm) registered during initial colonoscopy (V1).
- Advanced disease with high-grade dysplasia adenoma or even adenocarcinoma in situ that should required colectomy
- Signs of primary tuberculosis infection or respiratory infection
- Any other medical or psychological condition deemed incompatible with the proper conduct of the study according to the investigator.
- Contraindications to rapamycin use
- Participation in other biomedical research
- Deprivation of liberty of the legal guardians by judicial or administrative decision.
- Pregnancy, breastfeeding
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
France · 4 centers
- CHU Bordeaux Hôpital Pellegrin — Bordeaux
- CHU Montpellier Hôpital Arnaud de Villeneuve — Montpellier
- APHP Hôpital Robert Debré — Paris
- CHU Toulouse Hôpital des Enfants — Toulouse
Identifiers
NCT: NCT06308445 · RC31/23/0388